Avacta cuts convertible bond debt with £3.67m payment

Accelerated Amortized Payment of Convertible Bond Installment

LONDON and PHILADELPHIA – July 9, 2026 – Avacta (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, confirms that it has received an accelerated payment notice from the convertible bond holder in respect of the January 2026 quarterly deferred convertible bond repayment,  as referenced most recently in the financing announced on 5 June 2026, which the Company has elected to settle in cash. Accordingly, the Company has settled the accelerated quarterly amortization payment of £3.67 million representing principal of £2.4 million together with the associated interest and fees paylable in the deferrment.

After settlement of this quarterly repayment, the principal remaining under the convertible bond will be reduced to £16.8 million.

For further information from Avacta, please contact:

Avacta Group plc Christina Coughlin, Chief Executive Officer

https://avacta.com/ via Cohesion Bureau

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

---